Serotonin syndrome w/ irreversible nonselective MAOIs; reversible selective MAO-A inhibitor eg, moclobemide; reversible nonselective MAOI eg, linezolid; irreversible selective MAO-B inhibitor eg, selegiline; serotonergic medicinal products eg, tramadol, sumatriptan, other triptans. Lowered seizure threshold w/ TCAs, neuroleptics (eg, phenothiazines, thioxanthenes, butyrophenones), mefloquine, bupropion, tramadol. Enhanced effects w/ lithium, tryptophan. Increased AR incidence w/ St. John's wort. Altered anticoagulant effect w/ oral anticoagulants. Increased bleeding tendencies w/ NSAIDs. Increased risk of malignant arrhythmias w/ hypokalaemia-hypomagnesaemia-inducing medicinal products. Increased plasma conc w/ omeprazole, cimetidine; desipramine, metoprolol. Medicinal products prolonging QT interval eg, class IA & III antiarrhythmics; antipsychotics eg, phenothiazine derivatives, pimozide, haloperidol; TCAs; certain antimicrobial agents eg, sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, halofantrine; certain antihistamines eg, astemizole, mizolastine. Concomitant use w/ esomeprazole, fluvoxamine, lansoprazole, ticlopidine; flecainide, propafenone, clomipramine, nortriptyline, risperidone, thioridazine; CYP2C19-metabolised medicinal products. Not to be combined w/ alcohol.